Cargando…
Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis
Cost pressures and the need to demonstrate cost-effectiveness of new interventions require consideration of the costs of treating disease. This study presents analyses of resource use data covering 199 postmenopausal women who experienced a breast cancer recurrent event between 1991 and 2004 and wer...
Autores principales: | Karnon, J, Kerr, G R, Jack, W, Papo, N L, Cameron, D A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360350/ https://www.ncbi.nlm.nih.gov/pubmed/17653077 http://dx.doi.org/10.1038/sj.bjc.6603887 |
Ejemplares similares
-
Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK
por: Campbell, H E, et al.
Publicado: (2010) -
The total hospital and community UK costs of managing patients with relapsed breast cancer
por: Thomas, R J, et al.
Publicado: (2009) -
Cost-benefit of COVID-19 lockdown in the UK
Publicado: (2020) -
What sort of follow-up services would Australian breast cancer survivors prefer if we could no longer offer long-term specialist-based care? A discrete choice experiment
por: Bessen, T, et al.
Publicado: (2014) -
Estimated direct costs of COVID-19 pandemic high in Turkey, but true costs "undoubtedly higher"
Publicado: (2021)